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Abstract Objective: To analyze the
procedure of the informed consent
for ICU research obtained before ICU
admission. Design: Prospective,
open, observational study. Setting:
20-bed surgical ICU of a tertiary
teaching university hospital and the
ward before and after ICU. Patients:
Patients, scheduled for elective
cardiac surgery, who accepted to
participate in a coagulation study.
Interventions: Patients underwent
the same informed consent proce-
dure, including an oral presentation
of the coagulation study and an infor-
mative leaflet the day before surgery
on the ward. Measurements and
results: Between January and Au-
gust 2001, we included 38 patients;
36 survived ICU. Ten to 12 days
after surgery, 8/36 (22%) patients
did not know they had participated
in a study, and 9/36 (25%) could
not recall the study purpose and the
related risk. Patients with incomplete
recall stayed longer in ICU [median
(range): 4 (3–6) vs 3 (1–5) days;
p = 0.004]. None of these patients
(0/9 vs 10/27; p < 0.04) had read
the informative leaflet AND asked
at least one question during the
informed consent procedure. Con-
clusions: Even when the informed
consent is obtained in the most opti-
mal conditions for ICU research, its
ethical value remains questionable.
Indeed, a substantial number of pa-
tients were unaware of their study
participation, or of the related pur-
pose and risks. When the ICU stay is
prolonged, we should at least repeat-
edly and actively (re)-inform patients
about their study participation.
Introduction
Research is essential for the progress of medicine. Since
the declaration of Helsinki, international guidelines
require that informed consent be obtained from any
human research subject for his enrollment in a clinical
trial [1, 2]. The concept of informed consent includes
three essential rules that must be respected. First, the
patient has to receive adequate information about the
study, with a complete disclosure of the risks and ben-
efits from the investigator (disclosure) [3]. Second, the
patient should be able to understand the implications
of this research and the potential consequences of his
decision to participate (decision-making capacity) [4].
Third, the patient should be able to decide freely to
participate without any external pressure and to resign
from the study at any time without any consequences
on his care (voluntariness) [5]. In order to respect this
third principle, the patient has to be aware of his study
participation at any time. If these three criteria are not
fulfilled, we may question the ethical value of the informed
consent.
In recent years, especially after the publication of the
European Directive, the informed consent for research in
ICU has been repeatedly discussed [6, 7, 8]. Indeed, in
ICU patients, the severity of illness, multiple treatments,
the psychological burden and stressful environment may
interfere with any of the three criteria and, therefore, may
call into question the ethical value of the informed consent
given. Many ICU patients may fail to understand the infor-
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mation delivered [9, 10], or may be impaired in decision
making [11, 12].
Obtaining informed consent before the patient’s admis-
sion to ICU, whenever possible, may improve the proce-
dure and increase respect of the patient’s autonomy and
liberty to accept or decline. Thus, the elective surgery with
planned admission to ICU would be an ideal situation to
obtain informed consent for research in ICU.
Our hypothesis was that, even in this potentially ideal
situation, the ethical value of this informed consent may be
questionable. In order to test this hypothesis, we sought to
investigate whether patients would be able to mention hav-
ing participated in a study and to recall the essential study
components after inclusion. We further assessed the fac-
tors associated with the capacity to completely recall the
study information.
Materials and methods
Patients
The investigation about informed consent was part of
a study about coagulation in the surgical ICU after
heart surgery. This study consisted in assessing a new
coagulation management using a bedside analysis of
activated prothrombin time. Patients scheduled for elective
coronary artery bypass grafting or valvular surgery were
eligible. Those who refused to participate or had exclusion
criteria for the coagulation study were not considered for
the present study. Incompetent or non-French-speaking
patients, those with psychiatric disorders, senile dementia
or other intellectual disabilities were not included. To
give their consent to participate in the coagulation study,
patients needed a Glasgow coma scale (GCS) of 15, and to
be fully oriented and judged competent by the investigator.
Setting
The coagulation study was performed in a 20-bed general
surgical ICU of a tertiary teaching, university-affiliated
hospital, receiving 1,600 patients/year for a total of
6,000 hospital days/year and on the cardiovascular surgery
ward.
The informed consent procedure
All patients underwent the same informed consent pro-
cedure, performed by the same investigator, on the ward
the day before surgery. The information was given dur-
ing a 20-min individual oral presentation, in accordance
with a protocol. The investigator explained the study, in-
sisting on two study components: the purpose and the risk
for the patient. The defined keywords for the study pur-
pose were “coagulation” and “coagulation management.”
The study risk was of being anti-coagulated according to
the new coagulation-management strategy. We told the pa-
tient that, if he was in the study group, he would be treated
according to the results of the new bedside analysis. The
risk was minimal, because, if the result of the new bedside
analysis seemed incoherent, his doctor could refer to the
usual laboratory test.
The patient then received a one-page informative
leaflet. At the end of this procedure, the investigator
invited the patient to read the leaflet before signing the
informed consent form and to ask the investigator any
question the patient might have about the study. The
investigator noted whether the patient asked any question
and/or if he read the informative leaflet in his presence.
Because the information procedure was based on a pro-
tocol, and because of the inclusion criteria of the patients,
the disclosure of the information and the patient decision-
making capacity were assumed to be as optimal as possible
in the ICU environment.
Data collection
Age, gender, educational status, history of daily alcohol
intake, GCS and laboratory values (glycemia, creatinine,
bilirubin) upon admission to the ward, as well as medica-
tion during the 24 h before surgery (sedatives, analgesics,
other psychotropic drugs) were recorded.
Upon ICU admission, the type of cardiac surgery, the
durations of extracorporeal circulation and of aortic cross
clamping, and the Simplified Acute Physiological Score
second version (SAPS II) [13] were noted. The doses of
sedatives and analgesics used during the ICU stay, and
the lengths of mechanical ventilation and ICU stay, were
recorded.
Ten to 12 days after surgery, the same investigator as-
sessed, during an interview, whether the patient could re-
call his study participation and the study components. For
this interview, the patient had to present a Glasgow coma
scale (GCS) of 15, to be fully oriented and judged compe-
tent by the investigator.
Patients who could report their participation in the co-
agulation study, the study purpose and the related imposed
risk were assigned to the “complete recall” group. Patients
lacking one or more components were assigned to the “in-
complete recall” group.
Ethics issue
The coagulation study was approved by the ethics com-
mittee for human research of our institution, as was the
patient informative leaflet and the consent form. A specific
informed consent was not sought for the study about the
informed consent itself.
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Statistical analysis
For statistical analysis, StatView for Windows version
5.0.1 (SAS Institute, Cary, NC, USA) was used. Results
of patients with complete recall or with incomplete recall
were first compared separately with the two-tailed Fisher’s
exact test, the unpaired t-test or the Mann-Whitney U-test,
as appropriate. All tests were two-tailed, and a p value less
than 0.05 was considered significant. We further assessed
the sensitivity, specificity, positive predictive value, and
negative predictive value to predict the complete recall of
the study for particular factors.
Results
Between January and August 2001, we included 38 pa-
tients. Two patients died during the ICU stay (Fig. 1).
Consequently, we analyzed 36 patients who signed the
informed consent and were alive at day 12 after surgery.
Of the 36 patients, eight (22%) did not know they had
participated in a study at all. Among the 28 patients who
could report their study participation, 27 (75% of all
patients) could recall the essential study components, i.e.,
the study purpose and the related risk (Fig. 1).
Patients with complete recall did not differ from
patients with incomplete recall regarding their history
and demographic characteristics (Table 1). At the time
of the informed consent procedure, the laboratory values
and data regarding the current medication did not differ
between the two groups. Data regarding the cardiac
surgery were similar in both groups. Data at ICU ad-
Fig. 1 Distribution of patients included in
the coagulation study according to their
outcome (survived ICU or not) and their
ability to recall the study participation and
the study components (purpose and risk)
mission or during the ICU stay did not differ between
the two groups, except for their length of ICU stay.
Patients with complete recall stayed less time in ICU than
patients with incomplete recall [median (range): 3 (1–5)
vs 4 (3–6) days; p = 0.004]. The doses of morphine per
day, according to patient weight, and use of fentanyl and
benzodiazepines during the ICU stay were similar in the
two groups (Table 1).
More patients with complete recall had “read the in-
formative leaflet AND asked at least one question” during
the informed consent procedure [10/27 (37%) vs 0/9 (0%);
p = 0.04] (Table 2). The sensitivity, specificity, positive
predictive value, and negative predictive value of read-
ing the leaflet AND asking questions to detect patients
with complete recall were 37%, 100%, 100% and 35%,
respectively.
Discussion
As many as 22% of ICU patients who had consented to
participate in a study were unable to recall their study
participation, although they had given their informed
consent before the surgery and outside the stressful ICU
environment. This high rate is surprising. Indeed, patients
before an elective surgery were shown to feel less under
pressure and anxious and more likely to understand the
informative leaflet than patients before an emergency
surgery [14]. The most appropriate moment to obtain an
informed consent for clinical research in ICU patients
seemed to be before an elective ICU admission. Although
the patients in our study met this rare condition, the
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Table 1 Patients demographic, surgical and ICU data according to complete vs incomplete recall of the study (CABG coronary artery
bypass graft, ICU intensive care unit, SAPS II Simplified Acute Physiology Score)
Complete recall
of the study
(n = 27)
Incomplete recall
of the study
(n = 9)
p value
Demographic and anamnestic data
Age, years, mean ± SD 62 ± 10 68 ± 12 0.11 a
Male / female, n 24 / 3 6 / 3 0.15 b
Educational status:
Up to junior high school, n (%) 6 (22) 4 (44.5) 0.14 c
Intermediate (High School), n (%) 14 (52) 4 (44.5) -
University level or higher, n (%) 3 (11) 1 (11) -
Not available, n (%) 4 (15) 0 (0) -
Daily alcohol intake, n (%) 12 (44) 3 (33) 0.70 b
Surgery data
CABG, n (%) 25 (93) 8 (89) > 0.99 b
Valvular surgery, n (%) 2 (7) 1 (11) > 0.99 b
Duration of extracorporeal circulation, min, mean ± SD 120 ± 32 133 ± 37 0.29 a
Duration of aortic cross clamping, minutes, mean ± SD 75 ± 26 88 ± 33 0.20 a
ICU data
SAPS II, mean ± SD 23 ± 6 27 ± 9 0.10 a
Length of mechanical ventilation, (h) median (range) 9.5 (6–31.5) 9.5 (4–20) 0.21 d
Length of ICU stay, (days) median (range) 3 (1–5) 4 (3–6) 0.004 d
Morphine total dose, mg, mean ± SD 23 ± 13 32 ± 20 0.12 a
Morphine dose/ weight /day, mg/kg/24 h, mean ± SD 0.11 ± 0.61 0.11 ± 0.08 0.82 a
Administration of fentanyl, n (%) 1 (4) 0 > 0.99 b
Administration of midazolam, n (%) 6 (22) 3 (33) 0.66 b
Complete recall of the study: patients able to mention their study participation and study components
Incomplete recall of the study: patients not able to mention their study participation and study components
a Student’s t-test, b Fisher’s exact test, c X2test, d Mann–Whitney U-test
Table 2 Data at the time of informed consent and the attitude of the patients
Complete recall
of the study
(n = 27)
Incomplete recall
of the study
(n = 9)
p value
Data at the time of informed consent
Glycemia, mmol/l, mean ± SD 7 ± 2 6 ± 2 0.32 a
Creatinine, µmol/l, mean ± SD 84 ± 17 87 ± 67 0.71 a
Bilirubin, mmol/l, mean ± SD 11 ± 4 11 ± 5 0.92 a
Medication last 24 h
Benzodiazepines, n (%) 4 (15) 2 (22) 0.63 b
Morphine/ opioids, n (%) 0 0 > 0.99 b
“Attitude” of patients
Read leaflet before consent, n (%) 16 (59) 3 (33) 0.26 b
Asked at least one question before consent, n (%) 17 (63) 3 (33) 0.14 b
Read AND asked, n (%) 10 (37) 0 (0) 0.04 b
Did not read nor ask, n (%) 4 (15) 3 (33) 0.33 b
Complete recall of the study: patients able to mention their study participation and study components
Incomplete recall of the study: patients not able to mention their study participation and study components
a Student’s t-test, b Fisher’s exact test
proportion of patients unable to recall their study par-
ticipation was high compared with previous reports. In
the HERO-2 consent sub-study, only a small minority
of patients (6%) were unable to remember the consent
process. This difference of rate of recall may be due to the
different times elapsed between the consent process and
the second interview of the studies [15]. In other studies
including patients with acute myocardial infarction, the
rates of lack of recall were similar to our rate. However,
the informed-consent procedures were performed in
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a more stressful and urgent condition than was our consent
procedure [16, 17].
In our study, as many as 25% of patients had incom-
plete recall of the study components. Interestingly, almost
all patients either were able to recall the entire study or did
not recall the study at all. This finding led us to investigate
the potential factors associated with the lack of recall. In-
deed, it seems that the first step to improving the informed
consent procedure would be to assess the factors associated
with incomplete recall of the study and to act on them.
We found that age and educational status had no ef-
fect on recall of the study components, in contrast to pre-
vious studies where the rate of recall varied inversely with
age and directly with educational level [18, 19]. The in-
complete recall of the study was associated with a slightly
longer ICU stay but not with the use of drugs. This finding
suggests that, when a patient has a prolonged ICU stay, the
investigators should periodically verify that the patient is
aware of his participation in the study.
During this study, we found two relevant aspects that
may help in increasing the ethical value of informed con-
sent: interaction between the investigator and the patient,
and the active participation of the patient during the con-
sent procedure, by asking questions or by reading the in-
formative leaflet. When the patient had read the informa-
tive leaflet AND asked at least one question, we found that
he could always recall the complete information about the
study, with a positive predictive value of 100%. This is in
line with Flory’s findings that showed that spending time
to talk to the study participant appears to be the most ef-
fective way of improving his understanding [20].
Our study revives the debate about informed consent.
Indeed, the coagulation study could be considered trivial
regarding the risk for the patient, in the sense that the inves-
tigation was not invasive and the equipoise was obvious. In
this case, we could question, as did Dreyfuss, whether in-
formed consent is not more aimed at protecting the inves-
tigator than at protecting the patient [21]. Even if obtain-
ing informed consent is, in most cases, an essential way to
demonstrate respect for the patient’s autonomy, it can lead,
as suggested Truog, to some unnecessary and even silly
practices [22].
In all cases, the ethics committee has to weigh, on one
hand, the burden for the patient of the information obtained
and, on the other hand, the protection offered to the pa-
tient by informed consent. This protection of autonomy is
characterized by the possibility of refusing to participate
in the study and to withdraw without penalty. This respect
for potential and enrolled subjects is one of the seven re-
quirements to make clinical research ethical [23]. In any
case, informed consent is not sufficient for ethical clinical
research.
There are some study limitations. First, we analyzed
only a small number of patients, because this study was
part of a parent study about coagulation management in
ICU after cardiac surgery. This precluded the possibility of
a multivariate analysis to define further whether some fac-
tors may predict independently the complete recall of the
study 12 days after a major surgery. Second, we did not
investigate the recall of the patients who refused to partici-
pate in the coagulation-management study. Since there was
no consent in this case, we could not analyze the proce-
dure. Third, we did not assess the patient’s cognitive capac-
ity. There is good evidence that, when tested, the cognitive
capacity in ICU patients or sick patients is impaired [10,
11]. However, we performed our informed-consent proce-
dure before admission to ICU. Our patients were under-
going an elective cardiac surgery, and they were not in an
emergency situation, in contrast to other studies [9]. How-
ever, we cannot exclude that some cognitive impairment
could have been totally overlooked in our patients by the
investigator. Furthermore, spending more time with the pa-
tient to test his cognitive capacity and interacting with him
much longer than for a “standard” informed consent pro-
cedure would have biased our results. For the same reason,
we did not measure the patient’s memory.
Conclusion
In order to respect the principle of autonomy for informed
consent, the patient should be able to decide freely, with-
out any external pressure, whether he or she agrees to con-
tinue to participate in the study at any time. Even in the
present study, where the conditions of obtaining informed
consent were considered ideal for ICU research, more than
20% of patients were not aware of their study participation.
These findings suggest that we should encourage patients
to ask questions and read the informative leaflet during the
informed-consent procedure. In any case, especially when
the ICU stay is prolonged, we should repeatedly and ac-
tively (re)-inform patients about their study participation,
particularly if the study imposes some burden or risks over
time. Whether such interventions may increase the ethical
value of the informed consent in ICU research should be
further investigated.
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